Search Results - "Haglund, C."

Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update by Duffy, M.J., Lamerz, R., Haglund, C., Nicolini, A., Kalousová, M., Holubec, L., Sturgeon, C.

“…Biomarkers currently play an important role in the detection and management of patients with several different types of gastrointestinal cancer, especially…”
Get full text

Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy by JOHNSON, J. N, HOFMAN, N, HAGLUND, C. M, CASCINO, G. D, WILDE, A. A. M, ACKERMAN, M. J

“…Long QT syndrome (LQTS) typically presents with syncope, seizures, or sudden death. Patients with LQTS have been misdiagnosed with a seizure disorder or…”
Get full text

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report by Duffy, M.J., Sturgeon, C., Lamerz, R., Haglund, C., Holubec, V.L., Klapdor, R., Nicolini, A., Topolcan, O., Heinemann, V.

“…Pancreatic ductal adenocarcinoma is one of the most difficult malignancies to diagnose and treat. The aim of this article is to review how tumor markers can…”
Get full text

Prognostic role of CIP2A expression in serous ovarian cancer by Böckelman, C, Lassus, H, Hemmes, A, Leminen, A, Westermarck, J, Haglund, C, Bützow, R, Ristimäki, A

“…Background: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein expressed in several solid cancers. Our purpose was to study its role in…”
Get full text

Impact of pasireotide on postoperative pancreatic fistulas following distal resections by Vuorela, Tiina, Mustonen, H., Kokkola, A., Haglund, C., Seppanen, H.

“…Purpose Postoperative pancreatic fistula (POPF), a difficult complication after surgery, can cause peripancreatic fluid collection and infections in the…”
Get full text

Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use by Duffy, M.J, van Dalen, A, Haglund, C, Hansson, L, Holinski-Feder, E, Klapdor, R, Lamerz, R, Peltomaki, P, Sturgeon, C, Topolcan, O

“…Abstract The aim of this article is to present updated guidelines for the use of serum, tissue and faecal markers in colorectal cancer (CRC). Lack of…”
Get full text

Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreatic cancer patients by Mattila, N., Hisada, Y., Przybyla, B., Posma, J., Jouppila, A., Haglund, C., Seppänen, H., Mackman, N., Lassila, R.

“…Pancreatic ductal adenocarcinoma (PDAC) is associated with a hypercoagulable state and high mortality. Increases in the plasma levels of tumor marker…”
Get full text

Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer by Eurola, A., Ristimäki, A., Mustonen, H., Nurmi, A.-., Hagström, J., Haglund, C., Seppänen, H.

Get full text

Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients in Finland by Aaltonen, P., Carpén, O., Mustonen, H., Puolakkainen, P., Haglund, C., Peltola, K., Seppänen, H.

Get full text

Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry by Carpelan-Holmström, M, Nordling, S, Pukkala, E, Sankila, R, Lüttges, J, Klöppel, G, Haglund, C

“…Background: Worldwide survival data for ductal adenocarcinoma of the pancreas are the lowest among the 60 most frequent types of organ cancers. Hence published…”
Get full text

The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience by Seppänen, H., Juuti, A., Mustonen, H., Haapamäki, C., Nordling, S., Carpelan-Holmström, M., Sirén, J., Luettges, J., Haglund, C., Kiviluoto, T.

“…Objectives: Since the early 1990s, low long-term survival rates following pancreatic surgery for pancreatic ductal adenocarcinoma have challenged us to improve…”
Get full text

Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue by Häyry, V, Mäkinen, L K, Atula, T, Sariola, H, Mäkitie, A, Leivo, I, Keski-Säntti, H, Lundin, J, Haglund, C, Hagström, J

“…Background: The prognosis of squamous cell carcinoma of the oral tongue is poor and it would be beneficial to find prognostic markers to better adjust…”
Get full text

Expression and prognostic value of transcription factor PROX1 in colorectal cancer by Skog, M, Bono, P, Lundin, M, Lundin, J, Louhimo, J, Linder, N, Petrova, T V, Andersson, L C, Joensuu, H, Alitalo, K, Haglund, C H

“…Background: PROX1 is a specific target of the β -catenin/TCF pathway in the intestinal epithelium. It acts as a regulator of progression from a benign to a…”
Get full text

Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines by Duffy, M.J, van Dalen, A, Haglund, C, Hansson, L, Klapdor, R, Lamerz, R, Nilsson, O, Sturgeon, C, Topolcan, O

“…In recent years, numerous serum and cell/tissue-based markers have been described for colorectal cancer (CRC). The aim of this article was to provide…”
Get full text

High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer by Böckelman, C, Hagström, J, Mäkinen, L K, Keski-Säntti, H, Häyry, V, Lundin, J, Atula, T, Ristimäki, A, Haglund, C

“…Background: No reliable prognostic markers exist for squamous cell carcinoma of the tongue, and its prognosis can even in early stages be unpredictable and…”
Get full text

Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia by Österroos, A., Kashif, M., Haglund, C., Blom, K., Höglund, M., Andersson, C., Gustafsson, M.G., Eriksson, A., Larsson, R.

“…[Display omitted] Cytogenetic lesions often alter kinase signaling in acute myeloid leukemia (AML) and the addition of kinase inhibitors to the treatment…”
Get full text

Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors by Pulkkinen, V., Ezer, S., Sundman, L., Hagström, J., Remes, S., Söderhäll, C., Dario, G., Haglund, C., Kere, J., Arola, J.

“…Neuroendocrine tumors (NETs) arise from disseminated neuroendocrine cells and express general and specific neuroendocrine markers. Neuropeptide S receptor 1…”
Get full text

The Use of Blood Products in Adult Patients with Burns by Koljonen, V., Tuimala, J., Haglund, C., Tukiainen, E., Vuola, J., Juvonen, E., Lauronen, J., Krusius, T.

“…Introduction: Burn anemia represents a common complication following a burn injury. Burn anemia etiology carries distinct features occurring at each stage of…”
Get full text

High frequency of SNAIL-expressing cells confirms and predicts metastatic potential of phaeochromocytoma by Häyry, V, Salmenkivi, K, Arola, J, Heikkilä, P, Haglund, C, Sariola, H

“…Phaeochromocytomas are uncommon tumours of adrenal or extra-adrenal chromaffin tissue. About 2–26% of these have been reported to metastasize, but, on…”
Get full text

Endoscopic sphincterotomy and risk of cholangiocarcinoma: A population-based cohort study in Finland and Sweden by Strömberg, C, Böckelman, C, Haglund, C, Song, H, Ye, W, Nilsson, M

Get full text